Trial Information

Summary: A Phase II Study of Vorinstat (Suberoylanilide Hydroaxamic Acid)Plus Rituximab in Indolent Non-Hodgkin's Lymphoma

You have been asked to participate in this research study because you have an indolent (slow-growing) lymphoma that is newly diagnosed, has relapsed (returned after initially responding to chemotherapy) or is refractory (has failed to respond to standard therapy). The purpose of this study is to evaluate how often and for how long indolent lymphoma responds to treatment with vorinostat plus rituximab, to see what side effects vorinostat plus rituximab causes, and to study changes in laboratory tests during treatment. Your participation in this study is expected to last at least three weeks (one cycle of treatment). If you are tolerating treatment and your medical condition is not getting worse, you will be able to receive additional cycles of treatment. After you discontinue study treatment, your medical condition will continue to be followed for one year.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 3:02:28 PM